手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 医学研究 Volume 5, Issue 23. 2023.
促黄体生成素在控制性促排卵中的应用研究进展
作者 : 邓 超群, 韩宝 生*
DOI: 10.12361/2661-3603-05-23-152452
全部来源
获取全文
摘要 / Abstract
摘要：随着辅助生殖技术(Assisted Reproductive Technology,ART)的不断发展的和日趋完善，辅助生殖技术现已成为世界上公认的治疗不孕症的可靠方法。迄今为止国内外针对LH的添加已做出多项研究，但并无统一的建议。有学者提出内源性LH已足够支持卵泡的发育，无需额外添加LH，而另一些学者则认为血清LH水平(免疫活性)与其生物活性不成正比。因此在卵泡发育的过程应用黄体生成素的必要性以及解决其添加的相关问题成为研究热点。本文将针对LH的作用及其在辅助生殖技术控制性促排卵中的应用予以综述。
关键词 / Keywords
关键词：促黄体生成素；辅助生殖技术；体外受精胚胎移植；控制性促排卵
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1]Alviggi, Carlo, Ferraretti, Anna Pia, Conforti, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology： a systematic review[J].Fertility and Sterility： Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society,2018,109 (4) ：644-664.[2]FALCK B. Site of production of estrogen in rat ovary as studied in micro-transplants. Acta Physiol Scand Suppl. 1959;47(163)：1-101.[3]O'Dea L, O'Brien F, Currie K, Hemsey G.Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency： evidence of a threshold effect. Curr Med Res Opin. 2008[4]李媛，外源性黄体生成素补充治疗在超排卵中的应用［J］．生殖医学杂志，2013,22(10)：738-742.[5]Balasch J, Fábregues F.Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol. 2002 Jun;14(3)：265-74.[6]Shoham Z.The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002 Jun;77(6)：1170-7.[7]Johnson S, Schiffner J, Freundl G, et al. Luteinising hormone profiles in conception and non-conception natural cycles. Eur J Contracept Reprod Health Care. 2019 Apr;24(2)：140-147.[8]Mihm M, Evans AC. Mechanism for dominant follicle selection in monovulatory species： a comparison of morphological, endocrine and intraovarian events in cows, mares and women.Reprod Doments Anim,2008,43 Suppl 2：48-56.[9]Ho JY, Hwang JL, Chen MJ, etAL.What is the LH ceiling level for follicular growth arrest in late follicular phase.Hum rEPROD,2004,19 (2) ：463-4; author reply 464.[10]KULKE MH, ANTHONY LB, BUSHNELL DL, et al.NANETS treatment guidelines：well-differentiated neuroendocrine tumors of the stomachand pancreas[J].Pancreas,2010,39(6)：735-752.[11]YAMAGUCHI T, MACHIDA N, MORIZANE C, et al.Multicenter ret－rospective analysis of systemic chemotherapy for advanced neuron-doctrine carcinoma of the digestive system[J].Cancer Sci,2014,105 (9) ：1176-1181.[12]BERRUTI A, FAZIO N, FERRERO A, et al.Bevacizumab plus oc-trioxide and metronomic capecitabine in patients with metastaticwell-to-moderately differentiated neuroendocrine tumors：the xelbe－voct study[J].BMC Cancer,2014,14 (1) ：184.[13]DENG Y, YIN MN, LIANG PL, et al.Effects of luteinizing hormone supplementation on outcomes of in vitro fertilization and embryo transfer in patients undergoing GnRH-agonist long protocol[J].Nan Fang Yi Ke Da Xue Xue Bao,2017,37 (11) ：1501-1505.[14]CHOUHAN VS, DANGI SS, BABITHA V, et al.Stimulatory effect of Luteinizing hormone, insulin-like growth factor-1, and epidermal growth factor on vascular endothelial growth factor production in cultured bubaline luteal cells[J].Theriogenology,2015,84(7)：1212-1223[15]ITO T, HONMA Y, HIJIOKA S, et al.PhaseⅡstudy of lanreotide autogenic Japanese patients with unrespectable or metastatic well-differentiat－ed neuroendocrine tumors[J].Invest New Drugs,2017,35 (4) ：499-508.[16]HANFORD Y, MUSTAFA K, QUINN SL, et al.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors： patient select-tion and perspectives[J].Biologics,2017,11：115-122.[17]Franco J G Jr, Baruffi R L, Oliveira J B, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol： a matched case-control study[J].Reprod Biol Endocrinol, 2009,4 (7) ：58.[18]Bosch E, Vidal C, Labarta E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists-a randomized study[J].Hum. Reprod. 2008,23(10)：2346-2351.[19]NyboeAndersen A，Humaidan P，Fried G，et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre，prospective， randomized，controlled trial[J].Hum Reprod. 2008 Feb，23 (2) ：427-34.[20]Wong PC, Qiao J, Ho C, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy： an Asian perspective[J]. Reprod Biomed Online, 2011, 23 (1)： 81-90. DOI： 10.1016/j.rbmo.2011.03.023.[21]Ferraretti AP, Gianaroli L, Magli MC, et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril, 2004,82(6)：1521-6.[22]De Placido G, Alviggi C, Perino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod, 2005,20(2)：390-6[23]Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization： the Bologna criteria[J]. Hum Reprod, 2011, 26(7)： 1616-1624. DOI： 10.1093/humrep/der092.[24]Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders： is there a need for revision[J]. Hum Reprod, 2014, 29(9)： 1842-1845. DOI： 10.1093/humrep/deu139.[25]Lehert P, Kolibianakis EM, Venetis CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology： systematic review and meta-analysis. Reprod Biol Endocrinol, 2014,12：17.[26]田莉峰, 伍琼芳, 谭俊等. 早卵泡期长方案血清 LH 低的患者添加 r-LH 的临床结局分析. 生殖医学杂志, 2018,27(04)：310-315.[27]Pezzuto A, Ferrari B, Coppola F, et al. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol, 2010,26(2)：118-24.[28]He W, Lin H, Lv J, et al. The impact of luteinizing hormone supplementation in gonadotropin-releasing hormone antagonist cycles： a retrospective cohort study. Gynecol Endocrinol, 2018,34(6)：513-517.[29]Fábregues F, Creus M, Peñarrubia J, et al. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril, 2006,85(4)：925-31.[30]Shoham Z,Sm ith H, Yeko T, et al.Recom bi nant LH (lu tropin alfa) for the treatment of hypo gonadotrophic women with profound LH deficiency： a randomized, double-blind, placebo-controlled, proof-ofefficacy study[J].Clin Endocrinol(O xf) ,2008,69 (3) ：471-478.[31]Balasch J, Fabregues F, Carmona F, et al. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation： clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism. J Clin Endocrinol Metab,2009,94 (7) ：2367-73.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号